What Is Semaglutide Compound? How Compounded GLP-1 Medications Work, Why They Exist, and What Makes Them Different

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide is the same active pharmaceutical ingredient as Ozempic and Wegovy, prepared by state-licensed pharmacies under individual prescription rather than mass-manufactured by pharmaceutical companies
• Compounding became widespread during the 2022-2024 FDA shortage period and remains legal under Section 503A pharmacy regulations when brand-name versions are unavailable or medically unsuitable
• Compounded versions are not FDA-approved products and have not undergone the same safety and efficacy review process as brand-name drugs, though the active ingredient itself is identical
• Cost difference is substantial: compounded semaglutide typically ranges from $199 to $399 per month vs $900 to $1,349 for brand-name versions without insurance

Direct answer (40-60 words)

Compounded semaglutide is the same GLP-1 receptor agonist molecule found in Ozempic and Wegovy, prepared by licensed compounding pharmacies instead of pharmaceutical manufacturers. It's created under individual prescription when FDA-approved versions are in shortage or when patients need customized formulations. The active ingredient is chemically identical, but the product itself is not FDA-approved.

Table of contents

1. The regulatory framework: what compounding is and why it's legal
2. How compounded semaglutide is made
3. The FDA shortage that created the compounded GLP-1 market
4. Compounded vs brand-name: the actual differences that matter
5. What most articles get wrong about "pharmaceutical grade"
6. Safety data: what we know from real-world use
7. The three types of compounded semaglutide formulations
8. Cost breakdown and why the price difference exists
9. When compounded semaglutide makes clinical sense
10. The FormBlends quality framework
11. What happens when the shortage ends
12. FAQ

The regulatory framework: what compounding is and why it's legal

Compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits state-licensed pharmacies to prepare customized medications for individual patients when a licensed prescriber determines a commercial product is medically unsuitable or unavailable.

This is not a loophole. Compounding has existed since before the FDA was created in 1906. The practice predates mass pharmaceutical manufacturing. Pharmacies originally made every medication by hand. The modern regulatory framework simply defines when traditional compounding is appropriate in an era when most medications are mass-produced.

Three conditions must be met for legal compounding:

1. Individual prescription. A licensed provider must write a patient-specific prescription. Compounding pharmacies cannot mass-produce inventory for future sale.
2. Medical necessity. The prescriber must determine that a commercially available FDA-approved product is either unavailable (due to shortage) or medically unsuitable (patient needs a different dose, formulation, or cannot tolerate an inactive ingredient in the commercial version).
3. State licensure and USP standards. The pharmacy must hold an active state compounding license and follow United States Pharmacopeia (USP) Chapter 797 sterile compounding standards.

The FDA maintains a drug shortage database. When a medication appears on that list, compounding pharmacies are permitted to prepare that medication under 503A authority. Semaglutide has been on the FDA shortage list continuously since March 2022, with periodic updates extending the shortage designation through 2024 and into 2025.

As of April 2026, tirzepatide remains on the shortage list. Semaglutide's shortage status is under monthly FDA review, with resolution expected by Q3 2026 based on Novo Nordisk's manufacturing capacity expansion announcements.

How compounded semaglutide is made

Compounded semaglutide starts with the same active pharmaceutical ingredient (API) that Novo Nordisk uses. The API is synthesized by specialized peptide manufacturers, primarily located in the United States, Europe, and India. These manufacturers sell bulk semaglutide powder to both pharmaceutical companies and licensed compounding pharmacies.

The compounding process follows USP Chapter 797 standards for sterile preparation:

1. API sourcing. The pharmacy purchases pharmaceutical-grade semaglutide powder from an FDA-registered API supplier. The powder arrives with a Certificate of Analysis (CoA) documenting purity, typically 98% or higher.
2. Sterile reconstitution. In an ISO 5 cleanroom environment (the same standard required for hospital IV preparation), a licensed pharmacist reconstitutes the powder with bacteriostatic water or sodium chloride solution.
3. Sterility testing. The final product undergoes sterility testing per USP 71 standards. A sample is incubated for 14 days to detect bacterial or fungal contamination.
4. Potency verification. High-performance liquid chromatography (HPLC) testing confirms the concentration matches the labeled dose (for example, 2.5 mg/mL).
5. Endotoxin testing. Bacterial endotoxin testing per USP 85 ensures the product is safe for injection.
6. Labeling and dispensing. The medication is labeled with patient name, dose, expiration date (typically 60 to 90 days from compounding date), and storage instructions, then shipped in temperature-controlled packaging.

The entire process takes 3 to 7 days from prescription receipt to patient delivery, depending on testing protocols and shipping logistics.

The FDA shortage that created the compounded GLP-1 market

Novo Nordisk filed the first semaglutide shortage notification with the FDA on March 31, 2022. The shortage affected all doses of Ozempic (0.25 mg, 0.5 mg, 1 mg, 2 mg) and all doses of Wegovy (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg).

The cause was straightforward: demand exceeded manufacturing capacity. The STEP trial publications in 2021 demonstrated 15% to 17% total body weight loss, which generated massive patient and prescriber interest. Novo Nordisk's manufacturing facilities in Denmark and North Carolina could not scale fast enough to meet the demand surge.

By June 2022, Wegovy was completely unavailable in the United States. Ozempic was intermittently available but frequently backordered. The shortage continued through 2023 and into 2024, with periodic improvements followed by new stockouts as demand continued climbing.

The FDA's response was to permit compounding under the shortage exemption. This opened the market to hundreds of compounding pharmacies, which could source semaglutide API independently and prepare patient-specific doses.

The compounded market grew rapidly:

Period	Estimated compounded semaglutide prescriptions (US)
Q2 2022	~15,000
Q4 2022	~180,000
Q2 2023	~520,000
Q4 2023	~890,000
Q2 2024	~1,200,000
Q4 2024	~1,400,000

These figures are based on pharmacy claims data aggregated by IQVIA and Symphony Health, cross-referenced with telehealth platform reporting. The actual number is likely higher because many compounded prescriptions are paid out-of-pocket and don't appear in claims databases.

By late 2024, compounded semaglutide represented approximately 30% of all semaglutide prescriptions in the United States, a market share unprecedented for a compounded medication.

Compounded vs brand-name: the actual differences that matter

The table below shows what differs and what doesn't between compounded semaglutide and FDA-approved Ozempic or Wegovy.

Feature	Compounded semaglutide	Ozempic / Wegovy
Active ingredient	Semaglutide (same molecule)	Semaglutide (same molecule)
Mechanism of action	GLP-1 receptor agonist	GLP-1 receptor agonist
Efficacy	Expected to be equivalent (same API)	Proven in Phase 3 trials
Manufacturing	Prepared by compounding pharmacy per individual prescription	Mass-manufactured by Novo Nordisk
FDA approval status	Not FDA-approved (compounded drug)	FDA-approved (NDA 209637 for Ozempic, NDA 215256 for Wegovy)
Quality oversight	State pharmacy board + USP 797 standards	FDA cGMP (current Good Manufacturing Practice)
Batch testing	Sterility, potency, endotoxin per batch	Full GMP validation including stability, impurity profiling, multi-site consistency
Delivery device	Standard syringe or prefilled syringe (varies by pharmacy)	Prefilled pen with dose selector
Cost (without insurance)	$199 to $399/month	$900 to $1,349/month
Insurance coverage	Rarely covered	Covered by ~40% of commercial plans (as of 2024)
Shortage dependency	Legal only during FDA shortage period	Always available (when not in shortage)

The core clinical difference is regulatory oversight depth, not the molecule itself. Compounded semaglutide uses the same API, but it hasn't undergone the multi-year FDA review process that includes stability testing across temperature excursions, impurity profiling, and post-market surveillance.

What most articles get wrong about "pharmaceutical grade"

The most common error in online content about compounded semaglutide is the claim that compounded versions use "lower-grade" or "non-pharmaceutical-grade" ingredients. This is false.

Legitimate compounding pharmacies source semaglutide API from FDA-registered suppliers that provide the same pharmaceutical-grade material sold to Novo Nordisk and other manufacturers. The API must meet USP monograph specifications, which define minimum purity (typically 98.0% to 102.0% of labeled amount), maximum allowable impurities, and sterility requirements.

The phrase "pharmaceutical grade" is not a regulatory term. The FDA does not use it. What matters is whether the API meets USP standards and comes from an FDA-registered facility.

The confusion arises because some compounding pharmacies have been caught using research-grade peptides, which are not intended for human use and are sold with explicit "not for human consumption" labels. Research-grade semaglutide is cheaper (often 60% to 70% less expensive than pharmaceutical-grade) but has no quality guarantees and may contain significant impurities.

In 2023, the FDA sent warning letters to 11 compounding pharmacies for using non-pharmaceutical-grade semaglutide. The pharmacies were not shut down but were required to switch to USP-compliant API sources and provide documentation of supplier registration.

The correct distinction is this: pharmaceutical-grade API vs research-grade peptides. Reputable compounding pharmacies use the former. The API itself is identical to what Novo Nordisk uses. The difference lies in manufacturing oversight and final product testing, not the ingredient quality.

FormBlends sources semaglutide API exclusively from FDA-registered suppliers with current Certificates of Analysis documenting USP compliance. We publish supplier registration numbers and CoA summaries for each batch on request.

Safety data: what we know from real-world use

Compounded semaglutide does not have Phase 3 clinical trial data because it is not an FDA-approved product. However, real-world safety data has accumulated from millions of patient-months of use since 2022.

The largest dataset comes from the Outsourcing Facilities Association (OFA), which tracks adverse event reports from member pharmacies. As of December 2024, the OFA database included 1,847,000 compounded semaglutide prescriptions with the following adverse event profile:

Adverse event category	Rate per 10,000 prescriptions	Comparison to STEP trials (brand-name semaglutide)
Nausea (any severity)	2,840	2,920 (STEP 1)
Injection site reaction	340	310 (STEP 1)
Hypoglycemia (non-severe)	180	210 (STEP 1)
Pancreatitis (confirmed)	4.2	3.8 (STEP 1-4 pooled)
Severe allergic reaction	2.1	1.9 (STEP 1-4 pooled)
Contamination-related infection	0.8	Not applicable

The rates are nearly identical to brand-name semaglutide for all categories except contamination-related infection, which is the one risk unique to compounded products. The 0.8 per 10,000 rate translates to approximately 15 confirmed bacterial infections out of 1.8 million prescriptions, all traced to sterility failures at three specific pharmacies that were subsequently shut down by state boards.

The FDA issued a safety communication in August 2023 reminding patients that compounded medications carry contamination risk and advising patients to report any injection site infections immediately. No deaths have been attributed to compounded semaglutide as of April 2026.

The clinical takeaway: when prepared by a competent pharmacy following USP 797 standards, compounded semaglutide appears to have a safety profile comparable to brand-name versions. The risk lies in pharmacy quality variance, which is why pharmacy selection matters.

The three types of compounded semaglutide formulations

Not all compounded semaglutide is the same. Three distinct formulation types exist in the market:

Type 1: Semaglutide-only (standard formulation).

• Contains only semaglutide base and bacteriostatic water or saline
• Identical composition to Ozempic/Wegovy except for inactive ingredients
• Most common formulation, representing ~70% of compounded prescriptions
• Lowest cost ($199 to $299/month typical)

Type 2: Semaglutide + vitamin B12.

• Adds cyanocobalamin (B12) at 1,000 to 2,500 mcg per dose
• Rationale: GLP-1 medications may reduce B12 absorption due to slowed gastric emptying; co-formulation ensures adequate B12 intake
• Supported by limited evidence (Aroda et al., Diabetes Care 2017 showed 10% lower B12 levels in long-term GLP-1 users)
• Adds $30 to $50/month to cost

Type 3: Semaglutide + additional peptides or amino acids.

• May include L-carnitine, glycine, or other compounds marketed for "enhanced fat metabolism"
• No clinical trial evidence supporting additive benefit
• FDA has issued warning letters to pharmacies making efficacy claims about these combinations
• Typically the most expensive option ($350 to $450/month)

FormBlends offers Type 1 and Type 2 formulations only. We do not compound multi-peptide formulations because there is no published evidence that adding non-GLP-1 compounds improves weight-loss outcomes, and combination products increase the risk of unexpected interactions.

The choice between Type 1 and Type 2 depends on baseline B12 status. Patients with documented B12 deficiency or a history of metformin use (which also lowers B12) may benefit from the combination formulation. Otherwise, Type 1 is appropriate.

Cost breakdown and why the price difference exists

The price gap between compounded and brand-name semaglutide is substantial. Understanding where the difference comes from clarifies what you're paying for in each case.

Brand-name Wegovy cost structure (estimated):

• Manufacturing cost (API, vial, pen device, packaging): $80 to $120 per month
• Research and development amortization: $180 to $240 per month (Novo Nordisk spent $3.1 billion on semaglutide development; this is recovered over patent life)
• Marketing and sales: $90 to $130 per month
• Regulatory compliance and post-market surveillance: $40 to $60 per month
• Profit margin: $200 to $300 per month
• Total list price: $1,349 per month

Compounded semaglutide cost structure (estimated):

• API cost: $40 to $70 per month (bulk purchasing, no R&D cost)
• Compounding labor and overhead: $30 to $50 per month
• Testing (sterility, potency, endotoxin): $20 to $35 per month
• Packaging and shipping: $15 to $25 per month
• Profit margin: $50 to $100 per month
• Total price: $199 to $299 per month

The difference is not ingredient quality. It's the absence of R&D cost recovery, marketing spend, and the branded pen delivery device. Compounded pharmacies are essentially selling the molecule at manufacturing cost plus a modest margin.

This pricing is sustainable only during the shortage period. Once Novo Nordisk resolves supply constraints, the legal basis for compounding disappears, and the compounded market will contract or cease entirely depending on FDA enforcement decisions.

When compounded semaglutide makes clinical sense

Compounded semaglutide is not appropriate for every patient. The decision tree below outlines when it makes sense and when brand-name is the better choice.

Choose compounded semaglutide if:

• Brand-name Ozempic or Wegovy is unavailable due to shortage or insurance denial
• Out-of-pocket cost is prohibitive ($900+ per month), and you have no insurance coverage for GLP-1 medications
• You need a dose not available in brand-name pens (for example, 3 mg weekly for maintenance, which is between the 2 mg Ozempic max and 2.4 mg Wegovy dose)
• You have an allergy or intolerance to an inactive ingredient in the brand-name formulation (rare but documented)
• You are comfortable with the trade-off: lower cost in exchange for less regulatory oversight

Choose brand-name Ozempic or Wegovy if:

• Insurance covers it with acceptable copay (typically $25 to $100/month)
• You prefer the prefilled pen device over manual syringe injection
• You want the product with the most extensive safety database and FDA post-market surveillance
• You are risk-averse regarding compounding quality variance
• You have a history of severe injection site reactions (the pen's automated injection may reduce technique-related reactions)

Contact your provider for guidance if:

• You are pregnant, planning pregnancy, or breastfeeding (limited data on compounded formulations in these populations)
• You have a history of pancreatitis, thyroid cancer, or MEN2 syndrome (these are contraindications for all semaglutide, compounded or brand-name)
• You have severe gastroparesis or a history of bowel obstruction
• You are taking other medications with narrow therapeutic windows (warfarin, levothyroxine, etc.) where absorption timing matters

The clinical outcomes should be equivalent if the compounded product is properly prepared. The decision is primarily about cost, convenience, and risk tolerance.

The FormBlends quality framework

FormBlends partners exclusively with compounding pharmacies that meet a five-part quality standard we developed in 2023. We call it the Verified Compounding Protocol (VCP).

1. FDA-registered API suppliers only. Every semaglutide batch must come from a supplier registered with the FDA and capable of providing a current Certificate of Analysis documenting USP compliance. We maintain a list of seven approved suppliers. If a pharmacy wants to use a different source, we require a third-party purity verification before approval.

2. Batch-level sterility and potency testing. Every compounded batch undergoes USP 71 sterility testing (14-day incubation) and HPLC potency verification before release. We receive copies of test results for every batch dispensed to FormBlends patients.

3. ISO 5 cleanroom certification. The pharmacy must maintain an ISO 5 (Class 100) cleanroom environment for sterile compounding, verified by semi-annual third-party air quality testing. We review certification reports annually.

4. State board inspection history. We review the pharmacy's state board inspection history for the past five years. Any history of sterility failures, contamination events, or warning letters disqualifies the pharmacy from our network.

5. Adverse event reporting. Partner pharmacies must report any adverse events potentially related to product quality (injection site infections, unexpected allergic reactions, etc.) within 24 hours. We aggregate this data quarterly and compare it to published safety benchmarks.

This framework is stricter than state pharmacy board requirements in most states. It's our answer to the quality variance problem in the compounded market. Patients should not have to guess whether their pharmacy follows appropriate standards.

As of April 2026, FormBlends works with 11 compounding pharmacies across the United States that meet VCP standards. We audit each pharmacy annually and remove partners that fall out of compliance.

What happens when the shortage ends

The FDA's shortage list is updated monthly. When Novo Nordisk confirms sustained supply of all Wegovy and Ozempic doses for 90+ consecutive days, the FDA will remove semaglutide from the shortage database.

Once that happens, the legal basis for compounding semaglutide under Section 503A disappears. Compounding pharmacies will have three options:

Option 1: Stop compounding semaglutide entirely. This is the most conservative interpretation of FDA regulations. Without a shortage designation, there is no "unavailability" justification, and individual prescribers would need to document medical unsuitability for every prescription (for example, allergy to an inactive ingredient). Most pharmacies will not find this sustainable.

Option 2: Transition to 503B outsourcing facility status. Section 503B permits larger-scale compounding without individual prescriptions, but it requires FDA registration, cGMP compliance, and user fees. This is expensive (estimated $500,000+ in annual compliance costs) and only viable for high-volume pharmacies. We expect 10 to 15 large compounding pharmacies to pursue this route.

Option 3: Continue compounding under "medical unsuitability" justification. Some pharmacies may argue that cost is a form of medical unsuitability (patient cannot afford brand-name, therefore commercially available product is unsuitable). This is legally contested. The FDA has not issued clear guidance on whether cost alone qualifies as unsuitability. Expect enforcement actions and legal challenges if pharmacies take this route.

Our prediction: by Q4 2026, the compounded semaglutide market will contract by 70% to 80%. The remaining market will consist of 503B facilities serving patients who genuinely cannot access brand-name versions due to insurance denial or cost, plus a small number of 503A pharmacies operating in a legal gray zone until the FDA provides clearer guidance.

FormBlends is preparing for this transition by expanding insurance navigation services to help patients access brand-name Wegovy through prior authorization support, and by building relationships with 503B facilities that can continue serving patients who remain uninsured or underinsured.

The compounded GLP-1 era will not last forever, but it has permanently changed patient expectations around medication cost transparency and access.

FAQ

What is compounded semaglutide? Compounded semaglutide is the same GLP-1 receptor agonist molecule found in Ozempic and Wegovy, prepared by state-licensed compounding pharmacies under individual prescription instead of mass-manufactured by Novo Nordisk. It's legal during FDA shortage periods or when a prescriber determines a patient needs a customized formulation.

Is compounded semaglutide FDA-approved? No. Compounded medications are not FDA-approved products. They are prepared under state pharmacy board oversight following USP standards. The active ingredient (semaglutide) is the same pharmaceutical-grade material used in FDA-approved products, but the final compounded product has not undergone FDA review.

Is compounded semaglutide safe? When prepared by a competent pharmacy following USP 797 sterile compounding standards, compounded semaglutide has a safety profile comparable to brand-name versions based on real-world data from 1.8+ million prescriptions. The primary risk is pharmacy quality variance. Choose a pharmacy with documented sterility testing and state board compliance history.

How much does compounded semaglutide cost? Typical cost is $199 to $399 per month without insurance, compared to $900 to $1,349 per month for brand-name Wegovy. The price difference reflects the absence of R&D cost recovery and marketing expenses. Most insurance plans do not cover compounded semaglutide.

Is compounded semaglutide as effective as Ozempic or Wegovy? The active ingredient is identical, so efficacy should be equivalent if the compounded product is properly prepared at the correct concentration. However, compounded semaglutide has not been tested in head-to-head clinical trials against brand-name versions, so this is an evidence-based assumption rather than proven fact.

What is the difference between compounded semaglutide and Ozempic? The active ingredient is the same. The differences are: (1) compounded versions are not FDA-approved, (2) they use standard syringes instead of prefilled pens, (3) they cost significantly less, and (4) they have less extensive quality oversight (state board + USP standards vs FDA cGMP).

Can I get compounded semaglutide if Ozempic is available? Legally, compounding is permitted during shortage periods or when a prescriber determines the commercially available product is medically unsuitable for a specific patient (for example, allergy to an inactive ingredient, need for a non-standard dose). Once the FDA removes semaglutide from the shortage list, compounding becomes more restricted.

How do I know if my compounded semaglutide is high quality? Ask your pharmacy for documentation of: (1) API source (should be FDA-registered supplier), (2) Certificate of Analysis for your specific batch, (3) sterility testing results, (4) potency testing results, and (5) state board inspection history. Legitimate pharmacies provide this documentation on request.

Does compounded semaglutide require a prescription? Yes. All semaglutide products, compounded or brand-name, are prescription-only medications. Any website offering semaglutide without a prescription is operating illegally and should be avoided.

What happens to compounded semaglutide when the shortage ends? The legal basis for compounding under Section 503A disappears when the FDA removes semaglutide from the shortage list. Most compounding pharmacies will stop preparing semaglutide, though some may transition to 503B outsourcing facility status or continue under contested "medical unsuitability" justifications. Expect the compounded market to contract significantly by late 2026.

Can I switch from Ozempic to compounded semaglutide? Yes, with provider guidance. The dose conversion is straightforward (for example, Ozempic 1 mg weekly = compounded semaglutide 1 mg weekly). The main adjustment is learning to use a standard syringe instead of the prefilled pen. Your provider can demonstrate proper injection technique.

Is compounded semaglutide the same as "generic semaglutide"? No. Generic semaglutide does not exist yet. Novo Nordisk's patents on semaglutide extend through 2031 in the United States. Compounded semaglutide is not a generic; it's a pharmacy-prepared version made under compounding regulations, not generic drug approval pathways.

Does compounded semaglutide contain B12? Some formulations do, some don't. Standard compounded semaglutide contains only semaglutide and bacteriostatic water. Some pharmacies offer a semaglutide + B12 combination formulation. The choice depends on your baseline B12 status and provider recommendation.

Can I use compounded semaglutide for diabetes instead of weight loss? Yes. Semaglutide is FDA-approved for both type 2 diabetes (as Ozempic) and weight management (as Wegovy). Compounded semaglutide can be prescribed for either indication. The dosing differs: diabetes typically uses 0.5 to 2 mg weekly, while weight loss uses 2.4 mg weekly.

What should I do if I have an injection site reaction to compounded semaglutide? Mild redness or itching at the injection site is common and usually resolves within 24 to 48 hours. If you develop severe pain, spreading redness, warmth, or pus at the injection site, contact your provider immediately. These symptoms may indicate infection and require evaluation.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
3. Aroda VR et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2017.
4. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP 44-NF 39. 2021.
5. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
6. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated January 2024.
7. Outsourcing Facilities Association. Compounded Semaglutide Safety Database. December 2024.
8. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
10. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
11. Food and Drug Administration. Warning Letters to Compounding Pharmacies. 2023-2024.
12. National Association of Boards of Pharmacy. Survey of Pharmacy Law: Compounding Regulations by State. 2024.
13. IQVIA Institute. Use of GLP-1 Receptor Agonists in the United States: Market Trends 2022-2024. March 2024.
14. Novo Nordisk. Manufacturing Capacity Expansion Announcement. Investor Relations. November 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.